Calcimimetic and vitamin D receptor agonist therapy associates with lower mortality and fractures in hemodialysis patients: an international DOPPS analysis

Clicks: 2
ID: 314528
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #108 of 129 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Evidence linking CKD-MBD therapies to hard clinical outcomes in hemodialysis remains limited. Treatment with vitamin D receptor activators (VDRA) and calcimimetics is often adjusted or discontinued in response to parathyroid hormone values, which complicates the evaluation of their associations with clinical outcomes in observational research. Methods Because VDRA/calcimimetic prescriptions change over time in response to CKD-MBD markers that also predict outcomes, data from Phases IV–VII (2009–2022) of the Dialysis Outcomes and Practice Patterns Study (DOPPS) were analyzed using marginal structural models with time-updated, four-category exposure status (neither use, VDRA only, calcimimetics only, or both) to investigate the hazard ratios (HR) associated with all-cause mortality, cardiovascular (CVD) mortality, bone fractures, and hip fractures. Results A total of 117,452 hemodialysis patients were included in the all-cause mortality analysis, 50,111 patients in the CVD mortality analysis, and 33,906 patients in the fracture analysis. Compared with neither use, VDRA-only use (HR 0.71, p<0.001), calcimimetics-only use (HR 0.76, p<0.001), and combination therapy (HR 0.58, p<0.001) were significantly associated with a reduced risk of all-cause mortality. For CVD mortality, VDRA-only (HR 0.83, p<0.001), calcimimetics-only (HR 0.71, p<0.001), and combination therapy (HR 0.71, p<0.001) were significantly associated with a lower risk of CVD mortality. For bone fractures, calcimimetics-only (HR 0.59, p<0.001) and combination therapy (HR 0.74, p<0.01) were associated with lower risk of fracture, whereas VDRA-only was not (HR 0.89, p=0.102). For hip fractures, only combination therapy was associated with lower hip fracture risk (HR 0.56, p<0.01), while VDRA-only (HR 0.93, p=0.494) and calcimimetics-only (HR 0.67, p=0.082) were not statistically significant. Exploratory subgroup analyses by baseline characteristics showed broadly similar directions of association, although several estimates were imprecise. Conclusions Calcimimetics and combination therapy were associated with lower fracture risk in addition to lower mortality, but these findings should be interpreted cautiously and regarded as hypothesis-generating.
Reference Key
openalex_W7161994979 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ken Iseri, Brian Bieber, Noriko Hida
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag164
URL
https://doi.org/10.1093/ckj/sfag164
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.